UBS Starts BMRN, RDEA, ARIA at Buy, ITMN, ACHN, HGSI, IRWD at Neutral

An analyst at UBS initiated coverage on a number of stocks in the Biotech & Drug sector Thursday morning:

• BioMarin (Nasdaq: BMRN) with a Buy rating and a $43 price target
  
• Ardea Biosciences (Nasdaq: RDEA) with a Buy rating and a $31 price target
  
• Ariad Pharma (Nasdaq: ARIA) with a Buy rating and a $20 price target
  
• InterMune (Nasdaq: ITMN) with a Neutral rating and a $13.50 price target
  
• Achillion Pharma (Nasdaq: ACHN) with a Neutral rating and a $11 price target
  
• Human Genome Sciences (Nasdaq: HGSI) with a Neutral rating and a $8 price target
  
• Ironwood Pharma (Nasdaq: IRWD) with a Neutral rating and a $14 price target

Check out our Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Evercore ISI Starts MongoDB (MDB) at Outperform
• BMO Capital Starts Impinj Inc (PI) at Outperform
• BMO Capital Starts Eaton Corporation (ETN) at Outperform